Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415397 | 0.79 | SMN1; SMN2 (0.79) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AHTT | |
| SCHEMBL7459479 | 0.79 | SMN1; SMN2 (1.00) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AHTT | |
| SCHEMBL10400926 | 0.78 | SMN1; SMN2 (0.49) | SMN1; SMN2L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL12415404 | 0.76 | SMN1; SMN2 (0.73) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AHTT | |
| SCHEMBL10905416 | 0.72 | SMN1; SMN2 (0.63) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AHTT | |
| SCHEMBL12415402 | 0.72 | SMN1; SMN2 (0.67) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AHTT | |
| SCHEMBL28310198 | 0.72 | RECQL (0.63) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AHTT | |
| SCHEMBL20676018 | 0.72 | SMN1; SMN2 (0.85) | SMN1; SMN2L3MBTL1ALDH1A1HTT | |
| SCHEMBL10400925 | 0.69 | SMN1; SMN2 (0.47) | SMN1; SMN2L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL27253358 | 0.69 | MEN1 (0.65) | SMN1; SMN2ALDH1A1CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | SMN1; SMN2 4226/4885L3MBTL1 2569/4885ALDH1A1 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.